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BACKGROUND: The concept of differing clinical phenotypes within Parkinson’s disease (PD) is well represented in the literature.
However, there is no consensus as to whether any particular disease phenotype is associated with an increased risk of mild
cognitive impairment (MCI) using the newly proposed Movement Disorders Society diagnostic criteria for this feature.
AIMS: To explore the expression of PD-MCI in relation to the heterogeneity of idiopathic PD.
METHODS: A cluster analysis incorporating a range of specific demographic, clinical and cognitive variables was performed on 209
patients in the early stages of PD (between Hoehn and Yahr stages I–III). Post hoc analyses exploring variables not included in the
clustering solution were performed to interrogate the veracity of the subgroups generated.
RESULTS: This study identified four distinct PD cohorts: a younger disease-onset subgroup, a tremor dominant subgroup, a non-
tremor dominant subgroup, and a subgroup with rapid disease progression. The present study identified a differential expression of
PD-MCI across these subgroups, with the highest frequency observed in the non-tremor dominant cluster. The non-tremor
dominant subgroup was also associated with a higher prevalence of freezing of gait, hallucinations, daytime somnolence, and rapid
eye movement sleep behavior disorder compared with other subgroups.
CONCLUSIONS: This study confirms the existence of heterogeneity within the early clinical stages of PD and for the first time
highlights the differential expression of PD-MCI using the newly defined diagnostic criteria for this feature. An improved
understanding of PD-MCI and its clinical relationships may lead to an improved understanding of the pathophysiology underlying
heterogeneity in PD.
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INTRODUCTION
Parkinson’s disease (PD) is a progressive neurodegenerative
disorder with a wide variety of clinical symptoms. In addition to
classic motor features (i.e., tremor, rigidity, bradykinesia, and
postural instability), non-motor symptoms are now widely
accepted as part of the clinical spectrum. However, the specific
pathophysiological processes underlying these features are not all
well understood.
Severe dopamine depletion in the striatum due to loss of
dopaminergic neurons in the nigrostriatal pathway is well
recognized as the predominant histological feature of PD,
regardless of the clinical phenotype. Dopamine has a key role in
the regulation of corticostriatal pathways and functional con-
nectivity is clearly important across a range of physical, cognitive,
limbic, and other processes.1 Thus the loss of this neurotransmitter
in PD is likely to account for many of the observed symptoms in
PD. However in addition to nigrostriatal loss, Lewy pathology and
neuronal loss across differing populations including cholinergic,
serotonergic, and noradrenergic structures are also recognized as
contributing factors to several motor (e.g., gait and balance) and
non-motor symptoms (e.g., cognitive and affective disturbances)
that are experienced by PD patients.2 These pathologies lead to
neurochemical deficits, thereby disrupting the modulation of
neuronal signaling across cortical and subcortical regions crucial
for normal motor and non-motor functioning.3
Mild cognitive impairment in PD
The identification of mild cognitive impairment (MCI) has been
increasingly recognized as a transitional state between normal
aging and dementia in other patient populations (e.g., Alzheimer’s
disease). In PD, MCI is a common manifestation that can be
present even at diagnosis and represents a significant risk factor
for the development of dementia (PDD).4
To facilitate early identification of the distinct PD cohort at risk
of developing PDD, a definition of MCI in PD (PD-MCI) has recently
been formulated. The definition of PD-MCI describes patients with
cognitive deficits who have preserved capacity for daily function-
ing and do not fulfill the criteria for PDD.5 It is anticipated that in
future these criteria may be used to identify those patients who
would benefit most from any potential dementia intervention
strategies.
PD-MCI and heterogeneity in PD
Although the existence of PD-MCI is widely recognized, the clinical
features associated with it have yet to be well characterized. The
concept of distinct clinical phenotypes in PD is well represented in
the literature.6–11 Certain characteristics, such as age of disease
onset and predominant motor subtypes, have been most widely
used to identify distinct PD cohorts, as well as their association
with cognitive impairment. In general, these studies indicate that
PD patients whose motor dysfunction is principally characterized
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by non-tremor features have more severe cognitive impairments
than those with tremor dominant symptoms. The effect of age of
onset on cognitive abilities in PD patients is more controversial.
Some studies have shown that patients with a younger age of PD
onset have more preserved cognitive performance compared with
those with older age of onset despite being of equivalent age.12
However, other work has reported that early onset PD patients
may have more severe cognitive impairments.13
Many of the previous studies exploring heterogeneity in PD
have utilized the classification of distinct cohorts based on an
arbitrary division of patients into prospectively defined subgroups,
which may lead to an inherent bias in their conclusions. To avoid
such limitations, data-driven analysis, which seeks to divide
patients into discrete clusters based on a number of disease
features that are assessed in conjunction with each other, can help
to minimize this bias. In general, previous studies based on the
data-driven approach have observed variable degrees of cognitive
impairment across the subgroups. However, none of these
existing studies were able to evaluate the presence of PD-MCI
as defined by the new diagnostic Movement Disorder Society
(MDS) criteria.5
As with cognitive impairment, various PD phenotypes may also
be associated with different risks and severities of other motor and
non-motor symptoms that are commonly comorbid (e.g., depres-
sion and sleep disturbances).14 The incidence of such symptoms
may aggravate pre-existing cognitive deficits, thereby increasing
the risk of MCI in a specific PD subgroup. Therefore, it is important
that such distinct relationships, if they exist, be explored as they
may reflect differing patterns of underlying pathological change.
Previous clinicopathological research has investigated the pro-
gression of pathology in PD subgroups and observed differences
in Lewy pathology and an association with non-motor symptoms
such as dementia and depression.8
In light of these issues, the current study aimed to explore the
differential expression of MCI and associated clinical symptoms
across PD subgroups derived using a data-driven cluster analysis
approach. This study focused on PD patients in the earlier clinical
stages given that clinical symptoms in patients with more
advanced PD can often be confounded by co-existent pathologies.
A greater understanding of how PD-MCI relates to heterogeneity
in PD would likely have implications on future studies regarding
the etiology of this emerging entity and for future neuroprotective
approaches targeting PDD. The identification of subgroups of
patients who are characterized by interrelated features of
cognitive impairment and other clinical symptoms may also offer
the prospect of more coordinated management addressing
patterns of disease rather than individual symptoms.
MATERIALS AND METHODS
Participants
This study included a total of 209 participants with PD between Hoehn and
Yahr stages (H & Y) I and III (144 men, 65 women; mean age= 66.68
(s.d. = 8.90); mean disease duration = 5.87 (4.92) years) from the Parkinson’s
Disease Research Clinic at the Brain and Mind Research Institute, University
of Sydney. The diagnosis of idiopathic PD was based on the United
Kingdom Parkinson’s Disease Society Brain Bank criteria, and was
confirmed by a neurologist (SJGL). Participants meeting MDS criteria for
PDD were excluded.15 Only participants with complete datasets were
included in the analysis. The research was approved by the Human
Research Ethics Committee of the University of Sydney, and written
informed consent was obtained from all participants.
Clinical assessment
All participants underwent neurological and neuropsychological assess-
ment as previously reported elsewhere.16 Patients were tested whilst on
their usual medications. The neurological evaluation rated participants
according to H & Y stages, and assessed them on the revised MDS Task
Force Unified Parkinson’s Disease Rating Scale (MDS-UPDRS). Details of age
at disease onset, symptoms at onset, disease duration, and medications
were also recorded. A detailed medication history was taken for descriptive
purposes. Of the 209 participants, 186 were taking medications for PD: 74
were treated with L-dopa monotherapy (one of whom also had
electroconvulsive therapy), whereas further 71 were taking L-dopa with
adjunctive medications (four of whom also had deep-brain stimulation)
including dopamine agonists (50 participants), monoamine oxidase
inhibitors (10 participants), catechol-O-methyl transferase inhibitors
(7 participants), antiparkinson agents (1 participant), and anticholinergics
(3 participants). Thirty-one participants taking L-dopa plus adjunctive
dopamine agonists were also taking catechol-O-methyl transferase
inhibitors, monoamine oxidase inhibitors, antiparkinson agents, or
benzodiazepine. Ten participants were treated with dopamine agonist
monotherapy. Of the 209 participants, 26 were also taking antidepressant
medications. Twenty-three participants were untreated.
Neuropsychological assessment
All patients underwent a neuropsychological battery comprising the
following tests: the revised National Adult Reading Test (an estimate of
premorbid intellectual functioning), Mini-Mental State Examination
(a measure of global cognitive function), Trail Making Test A (total time;
attention/visuomotor processing speed), Trail Making Test B (total time;
executive functioning), digit span subtest from the Wechsler Adult
Intelligence Scale-III (total score; working memory), Logical Memory I
(total score; memory), Logical Memory II (delayed recall total; memory),
Controlled Oral Word Association Test phonemic fluency (letters: FAS;
executive functioning), and Controlled Oral Word Association Test
semantic fluency (animals: total score; language).
Diagnosis of PD-MCI
A diagnosis of PD-MCI was made according to the recently proposed MDS
Task Force Level 1 criteria.5 PD-MCI was diagnosed when: (1) impairment
was observed on two or more neuropsychological tests, defined by at least
1.5 s.d. below premorbid level of cognitive functioning, and (2) subjective
cognitive problems were reported by patients or family members as
defined by a score of 1 or more on item 1 (cognitive impairment) of the
MDS-UPDRS part I. Sub-classification of PD-MCI was not performed as this
may only be completed when utilizing a Level 2 criteria neuropsycholo-
gical battery.
Self-report measures
All participants completed the Parkinson’s Disease Questionnaire (PDQ-39),
which measures health-related quality of life. This questionnaire consists of
39 items covering the following eight dimensions: mobility, activities of
daily living, emotional wellbeing, stigma, social support, cognition,
communication, and bodily discomfort. Scaled scores on the PDQ-39
range from 0 to 100, with higher scores indicating poorer quality of life.
Severity of depressive symptoms was derived from the 21-item Beck
Depression Inventory-II, and a cutoff score 13/14 was used to determine (at
least moderately) significant symptoms. The Epworth Sleepiness Scale was
used to measure daytime sleepiness. Scores are scaled between 0 and 24,
with a higher score indicating higher levels of daytime sleepiness. A cutoff
score of 10 was used to determine patients with excessive daytime
sleepiness.17 The Scales for Outcomes in PD-Sleep Scale (SCOPA-S) was
used to evaluate both daytime and night-time sleep disturbances. Scores
range from 0 to 18 for daytime sleepiness and 0 to 15 for night-time sleep
quality. Cutoff scores of 4/5 and 6/7 for the SCOPA-S (DS) and SCOPA-S
(NS) were used respectively to determine the presence of sleep
disturbances.18 To identify patients with rapid eye movement (REM) sleep
behavior disorder (RBD), the REM Sleep Behavior Disorder Screening
Questionnaire was used. Scores range between 0 and 13 (higher scores
indicate more severe symptoms), and a cutoff score of 5 was used.19 The
Freezing of Gait Questionnaire (FOG-Q) item 3 (‘Do you feel that your feet
get glued to the floor while walking, making a turn or when trying to
initiate walking (freezing)?’) was used to identify patients with freezing.
This measure has previously been shown to be a reliable screening tool for
identifying ‘freezers’, with a positive score indicating ‘freezers’. The Scales
for Outcomes in Parkinson’s disease-Psychiatric Complications (SCOPA-PC)
item 1 was used to identify patients who hallucinate and confirmed by a
score of 1 or more on item 2 (hallucinations and psychosis) of the MDS-
UPDRS part I.
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Derivation of variables included in the cluster analysis
Variables included in the cluster analysis comprised standardized values for
motor phenotype score, age of disease onset, rate of disease progression,
revised National Adult Reading Test, Mini-Mental State Examination,
Logical Memory II, Trail Making Test B, Beck Depression Inventory-II and
dopaminergic therapy. These variables were selected from a broad range
of phenotypic features that have been highlighted in previous studies as
being significant in disease heterogeneity.6,7
Rate of disease progression was derived from dividing the total MDS-
UPDRS score for sections I–III by the disease duration (years), in order to
allow comparison between patients with differing disease durations
assessed at only a single time point.6 We also compared tremor and
non-tremor symptoms with the motor phenotype score.6 The score was
obtained by dividing a patients’ tremor score by their non-tremor score.
Aligning with the approach used in previous research, only items with the
higher lateralized score (left or right) were selected. The tremor score
represents the severity of subjective tremor and objective tremor at rest
and during movements. This score consisted of the mean of items 23, 54 or
55 (depending on the highest lateralized score), and 59. The non-tremor
score assesses speech, facial expression, swallowing, ability to turn in bed,
postural stability, walking and posture, rigidity, and global spontaneity of
movement. This score was derived from the mean of items 28–44 (only
items with the highest lateralized score) of the MDS-UPDRS. Impairment on
the Trail Making Test B and Logical Memory II was defined as 1.5 s.d. below
normative data. In keeping with previous work, dopaminergic therapy was
calculated as an ordinal variable in the cluster analysis, with a pre-defined
scale ranging from 0 to 2.6 A score of 0 represented no treatment with L-
dopa or dopamine agonist (DA). A score of one was given to patients
taking below 1,000mg of L-dopa per day with/without a DA, or DA
monotherapy. A score of two represented L-dopa dose over 1,000mg with/
without concomitant DA.
Statistical analyses
Non-hierarchical (k-means) cluster analyses were performed between
2- and 5-cluster solutions, which have previously been considered clinically
useful in typing the spectrum of PD patients.7 The optimal number of
clusters was determined by local peaks of the cubic cluster criterion.
Subsequent post hoc analyses were undertaken to compare the patient
subgroups. The Kolmogorov–Smirnov test was performed to determine
normal distribution. One-way analysis of variance followed by unpaired
t-tests, or the Kruskal–Wallis test followed by Mann–Whitney U- tests
(depending on whether the variable met parametric assumptions) were
used to validate and further specify the obtained cluster solution. Post hoc
analyses were also performed to validate the solution found in the
exploratory cluster analysis. This included related independent variables
not included in the cluster analysis: age, disease duration, H & Y scale and
the cognitive impairment dimension of the PDQ-39. All analyses employed
an alpha level of P⩽ 0.05, and were two tailed.
RESULTS
Explorative cluster analysis
Using cubic cluster criterion, a four-cluster model was selected as
the most relevant: (1) a subgroup of patients with a younger age
of disease onset (YO), (2) a subgroup of tremor dominant (TD)
patients, (3) a subgroup of non-tremor dominant (NTD) patients,
and (4) rapid disease progression (RDP) subgroup. The character-
istics of the identified clusters are summarized in Table 1.
The frequency of significant depressive symptoms in this
sample was 27%. Cluster 1 comprised 45% of the sample. Patients
in this cluster were characterized by a younger disease onset,
compared to patients in the other three clusters. The second
patient profile (cluster 2) comprised 12% of the sample. Patients in
this cluster were characterized by having a tremor dominant
motor phenotype score, lower L-dopa dose, and no statistically
significant cognitive impairments. Cluster 3 comprised 23% of the
sample. Patients in this cluster were characterized by having a
non-tremor dominant motor phenotype score. These patients
showed cognitive impairment most clearly demonstrated by a
significantly lower Trail Making B score and Mini-Mental State
Examination score, as well as a higher L-dopa dosage. Cluster 4
comprised 21% of the sample. Patients in this subgroup
demonstrated a rapid course of disease progression but no
severe cognitive impairment or motor disability compared with
the other subgroups (Table 1). The L-dopa dose of these patients
was similar to the doses taken by the tremor dominant cohort, but
was significantly less than those that of the younger onset cohort,
and the non-tremor dominant cohort.
Validation of the cluster solution
Demographic and clinical variables including age, disease dura-
tion, H & Y score, and PDQ-39 score were used to confirm the
cluster solution determined by the explorative k-mean cluster
analysis (see Table 2). A comparison of mean age at assessment
among the four clusters showed significant differences. Pairwise
cluster comparisons indicated that YO patients had a significantly
lower mean age at assessment than those from the other clusters
—TD, NTD, and RDP, respectively (t= 5.17, Po0.001; t= 4.70,
P= 0.011; t= 31.70, Po0.001).
Mean-disease duration scores also showed significant differ-
ences across the clusters. Patients from the RDP cluster had a
significantly shorter duration of disease compared with those from
the YO, TD, and NTD clusters, respectively (U= 558.00, z=− 6.86,
Po0.001; U= 375.50, z=− 1.96, P= 0.05; U= 169.00, z=− 6.93,
Po0.001).
Table 1. Group characteristics for the four-cluster solution
YO TD NTD RDP Between-group differences
Total number (%) 93 (45%) 24 (12%) 48 (23%) 44 (21%) —
Age onset, years 56.63 (8.2) 62.28 (8.3) 59.86 (9.3) 69.87 (7.0) F= 26.22, df= 3, Po0.001
Rate of disease progression, years 5.29 (3.1) 7.49 (6.4) 4.61 (3.4) 17.77 (8.5) H= 87.23, df= 3, Po0.001
Motor phenotype 0.68 (0.6) 1.86 (0.7) 0.43 (0.4) 0.62 (0.5) H= 52.65, df= 3, Po0.001
NART-R, estimated full scale IQ 112.84 (8.9) 104.29 (11.5) 103.04 (8.9) 113.41 (9.6) H= 44.22, df= 3, Po0.001
MMSE, raw score 29.06 (1.0) 28.21 (1.4) 26.71 (1.4) 29.05 (1.1) H= 75.87, df= 3, Po0.001
LM2, z-score 0.16 (0.9) − 0.63 (0.9) − 0.76 (1.0) 0.36 (0.75) H= 42.01, df= 3, Po0.001
Trails B, z-score 0.37 (0.7) − 0.32 (1.4) − 1.58 (1.7) −0.49 (1.3) H= 58.03, df= 3, Po0.001
BDI-II, raw score 10.47 (7.1) 6.17 (6.0) 9.6 (5.9) 9.59 (6.5) H= 9.27, df= 3, P= 0.023
LEDD, mg/day 709.29 (482.7) 231.06 (258.9) 846.14 (513.4) 309.07 (260.1) H= 53.13, df= 3, Po0.001
Abbreviations: BDI-II, Beck Depression Inventory-II (higher scores indicate more severe symptoms); LEDD, L-dopa equivalent daily dose; LM2, Logical Memory II;
MMSE, Mini-Mental State Examination; NART-R, revised National Adult Reading Test; NTD, non-tremor dominant; RDP, rapid disease progression; TD, tremor
dominant; Trails B, Trail Making Test B; YO, younger age of disease onset.
Significant values are represented in bold. Values are mean (s.d.).
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A comparison of mean scores on the H & Y showed significant
differences among the four clusters. Patients from the TD cluster
had a significantly lower H & Y score than those from YO, NTD, and
RDP clusters, respectively (U= 685.50, z=− 3.17, P= 0.002;
U= 260.00, z=− 4.03, Po0.001; U= 308.50, z=− 3.04, P= 0.002).
Results on the PDQ-39 questionnaire also added validity to the
four-cluster solution, with patients from the four-cluster solution
demonstrating significant differences in self-reported cognitive
impairment. Patients from the NTD cluster had higher scores on
the ratings for cognitive impairment than those from the YO, TD,
and RDP clusters, respectively (U= 1512.50, z=− 3.15, P= 0.002;
U= 297.00, z=− 1.95, P= 0.50; U= 617.50, z=− 3.18, P= 0.001).
Frequency of PD-MCI
Substantial differences in the frequency of PD-MCI were observed
in different clusters. Patients from the NTD subgroup had the
highest frequency, with 26 out of 48 patients (54%) characterized
as having PD-MCI. This was followed by the TD subgroup, which
had 10 out of 24 patients (42%) diagnosed as PD-MCI. The
frequency of PD-MCI in the YO and RDP subgroups was 24% (22
out of 93 patients) and 25% (11 out of 44 patients), respectively.
Other clinical symptoms
Table 3 shows the percentage of patients in each cluster who
scored above the cutoff to indicate clinically significant symptoms
on the SCOPA-S (NS), SCOPA-S (DS), Epworth Sleepiness Scale,
REM Sleep Behavior Disorder Screening Questionnaire, or who
were categorized as manifesting symptomatology on the basis of
a positive answer to FOG-Q item 3, and SCOPA-PC item 1.
Substantial differences in frequencies were observed between
the NTD subgroup and the other subgroups on FOG-Q item 3,
SCOPA-PC item 1, SCOPA-S (DS), SCOPA-S (NS), Epworth Sleepi-
ness Scale, and REM Sleep Behavior Disorder Screening Ques-
tionnaire, with the NTD subgroup having the highest percentages
in these measures amongst the four subgroups (see Table 3).
DISCUSSION
Using a data-driven approach, this study is the first to report the
frequency of MCI across PD subgroups using the newly proposed
MDS diagnostic criteria. Consistent with previous findings,6,7 we
identified four distinct PD cohorts: (1) a younger disease-onset
subgroup, (2) a tremor dominant subgroup, (3) a non-tremor
dominant subgroup, and (4) a subgroup with rapid disease
progression. In addition to identifying the prevalence of PD-MCI
across these four subgroups, this study explored their associated
clinical relationships. Importantly, we demonstrated that the four
PD subgroups were associated with a differential expression of
PD-MCI with the highest PD-MCI frequency observed in the NTD
phenotype. This subgroup was also associated with the highest
prevalence of FOG, hallucinations, daytime somnolence and RBD
than the other subgroups.
Heterogeneity in PD with respect to predominant motor
phenotype is well represented in the literature.6–10 In support of
previous work, the NTD subgroup identified here exhibited greater
cognitive impairment compared with other subgroups.6,10 Most
importantly, a higher prevalence of PD-MCI was observed in this
subgroup affecting over half of the patients (54%). Such
differences in PD-MCI frequencies may reflect more profound
neuropathological lesions in patients with NTD symptoms, in
particular with regards to nigral pathology.20 Evidence from in vivo
dopaminergic imaging has confirmed more severe nigral pathology
in patients with NTD features, relative to TD patients.21 Given that
dopamine has a key role in the regulation of corticostriatal as well
as limbic (mesolimbic) and cortical (mesocortical) pathways, more
profound dopamine dysfunction is also likely to have greater
impact upon the functional connection between regions involved
in cognitive processes.1 Taken together, the interplay between
deficits in different dopaminergic systems may at least in part relate
to the disease heterogeneity observed in the present study.
In addition, the NTD subgroup was the only subgroup to
demonstrate deficits on the Trail Making Test B. This may indicate
more selective cognitive dysfunction (i.e., executive dysfunction)
that was not present in the other subgroups. The presence of
selective cognitive dysfunction in the NTD subgroup may reflect
greater dysfunction within the frontostriatal circuitry. However,
whether this select deficit in the NTD subgroup would confer an
increased risk for developing PDD remains to be proven. Indeed,
whereas previous research has reported that posterior-cortically
based cognitive deficits have a high likelihood of transitioning to
dementia, this may not be the case for selective executive
dysfunction.22,23 Longitudinal follow-up of NTD cohorts would
therefore be an important future direction, in order to establish
rates of transition to dementia in this subgroup, who appear to
manifest the highest prevalence of MCI.
Beyond the influences of dopaminergic pathology, it has
become increasingly apparent that PD is better described as a
multi-system neurodegenerative process that involves an inter-
play between a host of non-dopaminergic pathways, including
noradrenergic, serotonergic, and cholinergic cell populations.24,25
Previous neuropathological and neuroimaging studies have
suggested that degeneration of the cholinergic system may have
a major role in the etiology of non-tremor motor features in PD
including postural instability and gait.2,24 Involvement of the
cholinergic system has also been discussed extensively in
cognitive dysfunction and dementia in PD.2,24,26 Cortical acet-
ylcholinesterase is a reliable marker of cholinergic pathways and
depletion of this neurotransmitter system, as characterized by
positron emission tomography, has been found to correlate with
poorer executive and attentional functions, as well as more
general cognitive impairment.27 In fact, a recent study reported
that apart from more substantial dopaminergic deficits, PDD
patients also exhibited additional cholinergic deficits compared
with nondemented PD patients.26 Furthermore, adverse effects on
attentional and executive processes have been observed follow-
ing the administration of anticholinergic drugs in PD patients with
Table 2. Mean (s.d.) for variables used to validate the four-cluster solution
YO (N=93) TD (N= 24) NTD (N= 48) RDP (N=44) Between-group differences
Age, years 63.22 (8.6) 65.79 (8.8) 68.93 (8.1) 72.01 (7.3) F= 12.97, df= 3, Po0.001
Disease duration 6.59 (4.7) 3.51 (2.8) 9.07 (5.7) 2.14 (1.1) H= 71.02, df= 3, Po0.001
Hoehn and Yahr stage, raw score 1.96 (0.5) 1.54 (0.5) 2.17 (0.6) 1.99 (0.6) H= 18.39, df= 3, Po0.001
PDQ-39 cognitive impairment dimension
(Q 30–33), scaled score
22.78 (17.23) 22.57 (18.46) 33.59 (21.21) 20.39 (15.31) H= 13.03, df= 3, P=0.003
Abbreviations: NTD, non-tremor dominant; PDQ-39, Parkinson’s Disease Questionnaire; RDP, rapid disease progression; TD, tremor dominant; YO, younger age
of disease onset.
Significant values are represented in bold.
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mild cognitive symptoms.28,29 Considering the role of altered
cholinergic neurotransmission on motor and cognitive functioning
in PD, the higher PD-MCI prevalence in the NTD subgroup may
further reflect a more widespread pathology that includes
additional cholinergic denervation compared with other sub-
groups. However, it remains to be determined whether such
deficits act in isolation on discrete cognitive functions or
sequentially with nigral pathology.26
In addition to the cognitive deficits identified, results from the
present study demonstrated that patients in the NTD subgroup
also had a selective pattern of other motor and non-motor
symptoms including FOG, hallucinations, daytime somnolence,
and RBD as compared with the other subgroups. Finding
increased rates of FOG in the NTD patient subgroup is consistent
with previous work, which has demonstrated that PD patients with
initial NTD symptoms (i.e., bradykinesia and rigidity) rather than
those with TD symptoms were more likely to develop FOG.30 At
present the pathophysiology underlying FOG is not well under-
stood, although lesions of the dopaminergic and cholinergic
systems are thought to be critically involved.31
NTD patients were also more likely to experience hallucinatory
symptoms.6,7 Hallucinations in PD have traditionally been
considered as a dopamine-related phenomenon, with the first
line of management often involving a reduction in dopaminergic
medication. However, it is now apparent that the development of
hallucinations in PD patients may arise from the complex
neuropathology of advancing disease. A clinicopathological
correlation between well-formed visual hallucinations and high
densities of Lewy bodies in the amygdala and parahippocampus
has been described in previous research.32 Furthermore, a wide
range of neurotransmitter systems have also been implicated in
the pathogenesis of hallucinations in PD. For instance, choliner-
sterase inhibitors, such as Rivastigmine, have been documented as
improving hallucinatory symptoms in PD patients.33 Furthermore,
medications targeting other neurotransmitter systems, such as
Clozapine, an atypical antipsychotic with both antidopaminergic
and antiserotonergic properties as well as Pimavanserin, a
serotonin 2A receptor inverse agonist, have also been shown to
improve PD-related psychosis.34,35
The NTD subgroup was found to be associated with higher
prevalence of daytime somnolence and RBD than the other
subgroups. Although the higher prevalence of daytime somno-
lence and RBD in the NTD subgroup may be associated with their
higher L-dopa doses, which is a well-documented contributing
factor of sleep disturbances in PD,36,37 these symptoms may also
arise from disrupted neurobiological changes in the ascending
arousal system.38 Thus, it is likely that the pathophysiology of
these additional non-motor symptoms is related to a range of
neural pathways that are more affected in the NTD subgroup than
other subgroups.
Previous studies have shown strong links between cognitive
impairment, FOG, hallucinations, daytime somnolence, and RBD in
PD patients.39–41 The incidence of these features and PD-MCI in
the NTD subgroup and the number of previous studies associating
these features with the involvement of multiple but similar neural
pathways suggests common or parallel underlying pathological
processes. Alternatively, these features could arise secondary to, or
aggravated by other pathologies such as Alzheimer’s disease.42,43
Indeed the frequency of comorbid pathology at post-mortem is
significant44 but what is less well understood, is how such changes
might impact on the potential phenotypes. Similarly, whilst there
is some data highlighting the influence of genetic polymorphisms
on cognitive decline in PD, such as the α-Syn gene (SNCA)45 and
the catechol-O-methyl transferase gene,46 little is known on how
these might affect other phenotypic features. These findings have
important implications for further research regarding the differing
underlying pathophysiology in different subtypes and their
association with PD-MCI.
The RDP subgroup identified in this study matches a similar
profile of one that has been identified previously by a number of
independent research teams.6–8 The cluster analysis in the present
study produced a RDP subgroup that accounted for 21% of the
total sample, which falls within the range of previous studies.6,7,9,11
Again, RDP was associated with older than average age of disease
onset, intact cognitive functioning, and the taking of relatively
small doses of dopaminergic therapy. The association between an
older age at disease onset and a rapid course of disease
progression may be due to less compensatory function or brain
reserve and potentially less effective immunity to PD pathology.
Selikhova and colleagues8 carried out a clinicopathological study
of PD subgroups based on the data-driven subtype classification
proposed by Lewis et al.6 They found that unlike the other three
groups, non-Lewy body pathology (e.g., Alzheimer’s) and demen-
tia was not present in the RPD subgroup, and this subgroup had
significantly lower and more restricted Lewy body pathology than
the other subgroups. The current study extended previous
observations by confirming that this group was linked to a
relatively lower prevalence of PD-MCI, FOG, hallucinations,
daytime somnolence, and RBD. It remains unclear what
contributes most to these clinical differences in the RDP subgroup.
It is possible that this group harbors some cases of well-known PD
mimics, which can be very difficult to distinguish clinically such
as Multiple System Atrophy.47 Future research exploring the
longitudinal progression and neuropathological basis for the rapid
progression of this subgroup will be necessary.
The majority of patients (45%) in the present study were
classified as being of YO, which is similar to rates reported
elsewhere 29–61%.6,7,9,11 This proportion may be artificially
inflated by the greater likelihood that such patients will more
actively volunteer to participate in research studies. The finding
Table 3. Frequencies of PD-MCI and other clinical features in the four-cluster solution
YO (N= 93), % TD (N = 24), % NTD (N= 48), % RDP (N = 44), %
PD-MCI 24 42 54 25
FOG-Q item 3 41 8 69 25
SCOPA-PC item 1 and revised MDS-UPDRS item 2 11 4 23 7
SCOPA-S (NS) 19 17 17 18
SCOPA-S (DS) 24 25 40 16
ESS 22 17 46 25
REMSBD 41 29 56 32
Abbreviations: ESS, Epworth Sleepiness Scale; FOG-Q, Freezing of Gait Questionnaire; MDS-UPDRS, Movement Disorder Society Task Force Unified Parkinson’s
Disease Rating Scale; NTD, non-tremor dominant; PD-MCI, mild cognitive impairment in Parkinson's disease; RDP, rapid disease progression; REMSBD, REM
Sleep Behavior Disorder Screening Questionnaire; SCOPA-PC, Scales for Outcomes in Parkinson’s disease-Psychiatric Complications; SCOPA-S (NS), Scales for
Outcomes in PD-Sleep Scale night-time sleepiness subscale; SCOPA-S (DS), Scales for Outcomes in PD-Sleep Scale daytime sleepiness subscale; TD, tremor
dominant; YO, younger age of disease onset.
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that the YO subgroup had more preserved cognitive function is
also aligned with previous reports.6,7 In addition, the current study
extends this observation by demonstrating the relatively lower
prevalence of PD-MCI (24%) in this phenotype compared with
other subgroups. However, given that this subgroup were
significantly younger than those in the other three subgroups, it
remains to be investigated whether these patients are able to
retain such clinical advantage as they age. Indeed, whilst relatively
few patients with early onset PD in the Selikhova et al.8
clinicopathological study developed dementia over the first 10–
15 years of the disease, a substantial number of them eventually
had developed features of advanced PD including cognitive
disability as they aged. Similarly, longitudinal research has
reported that most patients eventually develop PDD at ~ 70 years
of age irrespective of the time of PD onset.48 On the contrary,
evidence from genetic and epidemiological research showed that
this was not the case in the majority of YO PD patients with
PARKIN mutations, which are the most common cause of YO PD.49
Limitations
This study employed Level 1 diagnostic criteria for PD-MCI, and
therefore MCI subtyping (e.g., amnestic versus non-amnestic) was
beyond the current scope of research conducted here. Exploring
MCI subtypes as they manifest across different clinical phenotypes
will be a key next step in understanding the interaction between
heterogeneity and cognitive impairment in PD. However, whilst
the employment of additional neuropsychological tests may
increase characterization of PD-MCI subtype, the administration
of a more comprehensive battery of neuropsychological tests may
not always be practical or available due to the long administration
time and the increased possibility of fatigue, particularly in this
older population.16
Another limitation of this study relates to the relatively low
prevalence of depression in the current sample (27%), as compared
with that of ~ 40%50 shown in previous research. However, it is
noted that we used Beck Depression Inventory-II cutoff scores for
moderate symptomatology in this study, as opposed to a
Diagnostic and Statistical Manual of Mental Disorders—Fourth
Edition diagnosis and thus our findings are not directly comparable.
In addition, future studies incorporating neuropathological investi-
gations and exploration of predisposing genetic polymorphisms
will also be critical in establishing the shared and unique
pathological signatures of PD-MCI across the clinical phenotypes.
This is particularly relevant as most neuropathological research to
date has been focused on TD and NTD subgroups, so there are only
scant data on the neuropathological correlates of YO and RDP
subgroups. A prospective longitudinal clinicopathological follow-up
of the cases studied here is being undertaken, which hopefully will
eventually provide insight into the factors contributing to the
neurobiology underpinning these distinct clinical subgroups.
In conclusion, using a data-driven approach this study
confirmed the existence of heterogeneity within the early clinical
stages of PD with four subgroups: (1) YO, (2) TD, (3) NTD, and (4)
RDP; and importantly, this describes the differential expression of
PD-MCI and other clinical symptoms across the identified
subgroups. Nevertheless, rather than as a definitive classification
system, the existence of these subgroups serves more as a
platform for testing hypotheses. Avoiding the inclusion of key
neuropsychiatric features such as hallucinations, as variables in the
clustering solution was intended to allow the exploration of the
subgroups generated without the significant influences of
symptoms that would be regarded as less frequent in an early
clinical disease sample. The confirmation of these subgroups may
suggest the presence of different patterns of neuropathology that
are likely to influence prognosis and response to treatment and
provide an impetus for determining these clinicopathological
correlations. Our current findings suggest that it is important to
take into account the subgroup of individual patients when
evaluating PD-MCI so as to better direct their specific manage-
ment by taking into consideration the constellation of clinical
symptoms that are likely to coexist and impact on quality of life.
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